{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:23:59Z","timestamp":1792153439769,"version":"4.4.0"},"reference-count":8,"publisher":"Georg Thieme Verlag KG","issue":"06","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dtsch Med Wochenschr"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:title>Was ist neu?<\/jats:title><jats:p>\n          Einteilung der Minimal-Change-Disease und fokalen und segmentalen Glomerulosklerose\u2002Das zunehmende Wissen \u00fcber die verschiedenen Ausl\u00f6ser der MCD und FSGS spiegelt sich in den neuen KDIGO-Leitlinien wider, welche eine klare Einteilung der (MCD und) FSGS in prim\u00e4re, sekund\u00e4re und genetische Ursachen vorsieht. Die korrekte Klassifizierung ist wichtig und hat eine direkte Auswirkung auf die Therapie.<\/jats:p><jats:p>\n          Therapie\u2002Die Therapie besteht bei der prim\u00e4ren MCD und FSGS weiterhin aus Steroiden oder \u2013 bei Nichtansprechen bzw. Kontraindikationen \u2013 aus Calcineurin-Inhibitoren, Mycophenolatmofetil oder Cyclophosphamid. Auch Rituximab findet in refrakt\u00e4ren F\u00e4llen als \u201eOff-Label\u201c Verwendung. Bei sekund\u00e4ren Formen wird die Grunderkrankung behandelt.<\/jats:p><jats:p>\n          Ausblick\u2002Mit Sparsentan befindet sich ein neuer Wirkstoff in der klinischen Testung. Bereits jetzt k\u00f6nnen SGLT-2-Inhibitoren verschrieben werden, um einen eGFR-Verlust zu minimieren. Die zeitnahe (kinder-)nephrologische Anbindung von Patienten mit MCD\/FSGS ist f\u00fcr das Outcome von gro\u00dfer Bedeutung. Durch das nationale FOrMe-Register stehen regionale Experten f\u00fcr die Behandlung der MCD und FSGS zur Verf\u00fcgung.<\/jats:p>","DOI":"10.1055\/a-1334-2135","type":"journal-article","created":{"date-parts":[[2022,3,15]],"date-time":"2022-03-15T23:42:17Z","timestamp":1647387737000},"page":"332-336","source":"Crossref","is-referenced-by-count":3,"title":["Nephrotisches Syndrom: \u00dcberblick und Basis"],"prefix":"10.1055","volume":"147","author":[{"given":"Paul","family":"Diefenhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Osterholt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Brinkk\u00f6tter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2022,3,15]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1136\/bmj.39576.709711.80","article-title":"Nephrotic syndrome in adults","volume":"336","author":"R P Hull","year":"2008","journal-title":"BMJ"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","article-title":"KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases","volume":"100","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group","year":"2021","journal-title":"Kidney Int"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1038\/nrneph.2016.147","article-title":"Minimal change disease and idiopathic FSGS: manifestations of the same disease","volume":"12","author":"R J Maas","year":"2016","journal-title":"Nat Rev Nephrol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/s41581-021-00427-1","article-title":"Therapeutic trials in adult FSGS: lessons learned and the road forward","volume":"17","author":"A S de Vriese","year":"2021","journal-title":"Nature reviews. Nephrology"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2215\/CJN.06180519","article-title":"Randomized, Controlled Trial of Tacrolimus and Prednisolone Monotherapy for Adults with De Novo Minimal Change Disease: A Multicenter, Randomized, Controlled Trial","volume":"15","author":"N R Medjeral-Thomas","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12882-020-01797-7","article-title":"Rituximab therapy for focal segmental glomerulosclerosis and minimal change disease in adults: a systematic review and meta-analysis","volume":"21","author":"P Hansrivijit","year":"2020","journal-title":"BMC Nephrol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in Patients with Chronic Kidney Disease","volume":"383","author":"H JL Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1681\/ASN.2018010091","article-title":"DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS","volume":"29","author":"H Trachtman","year":"2018","journal-title":"J Am Soc Nephrol"}],"container-title":["DMW - Deutsche Medizinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1334-2135.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,15]],"date-time":"2022-03-15T23:43:51Z","timestamp":1647387831000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1334-2135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":8,"journal-issue":{"issue":"06","published-online":{"date-parts":[[2022,3,15]]},"published-print":{"date-parts":[[2022,3]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1334-2135","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0012-0472","1439-4413"],"issn-type":[{"value":"0012-0472","type":"print"},{"value":"1439-4413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3]]}}}